Investigating a new treatment for neurological and psychiatric disorders through mGlu7 receptor modulation
Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders
This study is looking at a special brain receptor that could help improve thinking and behavior in people with conditions like autism and Rett syndrome by testing a new compound that might reduce anxiety, boost cognitive skills, and lessen seizures.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10884237 on NIH RePORTER |
What this research studies
This research focuses on the metabotropic glutamate receptor 7 (mGlu7), which plays a crucial role in neurotransmitter release and synaptic plasticity in the brain. The study aims to develop small molecule positive allosteric modulators (PAMs) that enhance mGlu7 activity, potentially correcting cognitive and behavioral issues associated with neurodevelopmental disorders. By using a selective compound, VU6027459, the research will explore its effects on symptoms such as anxiety, cognitive deficits, and seizures in preclinical models. Patients may benefit from advancements in treatment options for conditions like autism and Rett syndrome.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with neurodevelopmental disorders such as autism spectrum disorder or Rett syndrome.
Not a fit: Patients with conditions unrelated to the mGlu7 receptor or those who do not have neurodevelopmental disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with neurological and psychiatric disorders, improving their quality of life.
How similar studies have performed: Previous research has shown promise in targeting mGlu7 for treating related conditions, indicating potential for success with this approach.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Niswender, Colleen M — Vanderbilt University
- Study coordinator: Niswender, Colleen M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.